Butler covers the Healthcare sector, focusing on stocks such as Quoin Pharmaceuticals, Aquestive Therapeutics, and Gamida Cell. According to TipRanks, Butler has an average return of -1.4% and a 43.26% success rate on recommended stocks.
Currently, the analyst consensus on Aquestive Therapeutics is a Strong Buy with an average price target of $5.67.
The company has a one-year high of $6.40 and a one-year low of $0.62. Currently, Aquestive Therapeutics has an average volume of 922.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
Read More on AQST: